Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Licofelone Enhances the Efficacy of Paclitaxel in Ovarian Cancer by Reversing Drug Resistance and Tumor Stem-like Properties.

Hirst J, Pathak HB, Hyter S, Pessetto ZY, Ly T, Graw S, Koestler DC, Krieg AJ, Roby KF, Godwin AK.

Cancer Res. 2018 Aug 1;78(15):4370-4385. doi: 10.1158/0008-5472.CAN-17-3993. Epub 2018 Jun 11.

PMID:
29891506
2.

Drug discovery using clinical outcome-based Connectivity Mapping: application to ovarian cancer.

Raghavan R, Hyter S, Pathak HB, Godwin AK, Konecny G, Wang C, Goode EL, Fridley BL.

BMC Genomics. 2016 Oct 19;17(1):811.

3.

Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.

Zook P, Pathak HB, Belinsky MG, Gersz L, Devarajan K, Zhou Y, Godwin AK, von Mehren M, Rink L.

Clin Cancer Res. 2017 Jan 1;23(1):171-180. doi: 10.1158/1078-0432.CCR-16-0529. Epub 2016 Jul 1.

4.

A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer.

Pathak HB, Zhou Y, Sethi G, Hirst J, Schilder RJ, Golemis EA, Godwin AK.

PLoS One. 2015 Dec 4;10(12):e0144126. doi: 10.1371/journal.pone.0144126. eCollection 2015.

5.

PTN signaling: Components and mechanistic insights in human ovarian cancer.

Sethi G, Kwon Y, Burkhalter RJ, Pathak HB, Madan R, McHugh S, Atay S, Murthy S, Tawfik OW, Godwin AK.

Mol Carcinog. 2015 Dec;54(12):1772-85. doi: 10.1002/mc.22249. Epub 2014 Nov 21.

6.

Acculturative stress and inflammation among Chinese immigrant women.

Fang CY, Ross EA, Pathak HB, Godwin AK, Tseng M.

Psychosom Med. 2014 Jun;76(5):320-6. doi: 10.1097/PSY.0000000000000065.

7.

Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion.

Do TV, Xiao F, Bickel LE, Klein-Szanto AJ, Pathak HB, Hua X, Howe C, O'Brien SW, Maglaty M, Ecsedy JA, Litwin S, Golemis EA, Schilder RJ, Godwin AK, Connolly DC.

Oncogene. 2014 Jan 30;33(5):539-49. doi: 10.1038/onc.2012.632. Epub 2013 Jan 21.

8.

An RNA interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancer.

Sethi G, Pathak HB, Zhang H, Zhou Y, Einarson MB, Vathipadiekal V, Gunewardena S, Birrer MJ, Godwin AK.

PLoS One. 2012;7(10):e47086. doi: 10.1371/journal.pone.0047086. Epub 2012 Oct 9.

9.

Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Schilder RJ, Brady WE, Lankes HA, Fiorica JV, Shahin MS, Zhou XC, Mannel RS, Pathak HB, Hu W, Alpaugh RK, Sood AK, Godwin AK.

Gynecol Oncol. 2012 Oct;127(1):70-4. doi: 10.1016/j.ygyno.2012.06.009. Epub 2012 Jun 16.

10.

19p13.1 is a triple-negative-specific breast cancer susceptibility locus.

Stevens KN, Fredericksen Z, Vachon CM, Wang X, Margolin S, Lindblom A, Nevanlinna H, Greco D, Aittomäki K, Blomqvist C, Chang-Claude J, Vrieling A, Flesch-Janys D, Sinn HP, Wang-Gohrke S, Nickels S, Brauch H; GENICA Network, Ko YD, Fischer HP, Schmutzler RK, Meindl A, Bartram CR, Schott S, Engel C, Godwin AK, Weaver J, Pathak HB, Sharma P, Brenner H, Müller H, Arndt V, Stegmaier C, Miron P, Yannoukakos D, Stavropoulou A, Fountzilas G, Gogas HJ, Swann R, Dwek M, Perkins A, Milne RL, Benítez J, Zamora MP, Pérez JI, Bojesen SE, Nielsen SF, Nordestgaard BG, Flyger H, Guénel P, Truong T, Menegaux F, Cordina-Duverger E, Burwinkel B, Marmé F, Schneeweiss A, Sohn C, Sawyer E, Tomlinson I, Kerin MJ, Peto J, Johnson N, Fletcher O, Dos Santos Silva I, Fasching PA, Beckmann MW, Hartmann A, Ekici AB, Lophatananon A, Muir K, Puttawibul P, Wiangnon S, Schmidt MK, Broeks A, Braaf LM, Rosenberg EH, Hopper JL, Apicella C, Park DJ, Southey MC, Swerdlow AJ, Ashworth A, Orr N, Schoemaker MJ, Anton-Culver H, Ziogas A, Bernstein L, Dur CC, Shen CY, Yu JC, Hsu HM, Hsiung CN, Hamann U, Dünnebier T, Rüdiger T, Ulmer HU, Pharoah PP, Dunning AM, Humphreys MK, Wang Q, Cox A, Cross SS, Reed MW, Hall P, Czene K, Ambrosone CB, Ademuyiwa F, Hwang H, Eccles DM, Garcia-Closas M, Figueroa JD, Sherman ME, Lissowska J, Devilee P, Seynaeve C, Tollenaar RA, Hooning MJ, Andrulis IL, Knight JA, Glendon G, Mulligan AM, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, John EM, Miron A, Alnæs GG, Kristensen V, Børresen-Dale AL, Giles GG, Baglietto L, McLean CA, Severi G, Kosel ML, Pankratz VS, Slager S, Olson JE, Radice P, Peterlongo P, Manoukian S, Barile M, Lambrechts D, Hatse S, Dieudonne AS, Christiaens MR, Chenevix-Trench G; kConFab Investigators; AOCS Group, Beesley J, Chen X, Mannermaa A, Kosma VM, Hartikainen JM, Soini Y, Easton DF, Couch FJ.

Cancer Res. 2012 Apr 1;72(7):1795-803. doi: 10.1158/0008-5472.CAN-11-3364. Epub 2012 Feb 13.

11.

Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death.

Ratushny V, Pathak HB, Beeharry N, Tikhmyanova N, Xiao F, Li T, Litwin S, Connolly DC, Yen TJ, Weiner LM, Godwin AK, Golemis EA.

Oncogene. 2012 Mar 8;31(10):1217-27. doi: 10.1038/onc.2011.314. Epub 2011 Jul 25.

12.

Novel surface targets and serum biomarkers from the ovarian cancer vasculature.

Sasaroli D, Gimotty PA, Pathak HB, Hammond R, Kougioumtzidou E, Katsaros D, Buckanovich R, Devarajan K, Sandaltzopoulos R, Godwin AK, Scholler N, Coukos G.

Cancer Biol Ther. 2011 Aug 1;12(3):169-80. Epub 2011 Aug 1.

13.

Insight into poliovirus genome replication and encapsidation obtained from studies of 3B-3C cleavage site mutants.

Oh HS, Pathak HB, Goodfellow IG, Arnold JJ, Cameron CE.

J Virol. 2009 Sep;83(18):9370-87. doi: 10.1128/JVI.02076-08. Epub 2009 Jul 8.

14.

Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash.

Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, Min H, Devarajan K, Ross E, Drescher CW, Godwin AK.

Gynecol Oncol. 2009 Apr;113(1):21-7. doi: 10.1016/j.ygyno.2008.12.003. Epub 2009 Jan 21.

15.

Picornavirus genome replication: roles of precursor proteins and rate-limiting steps in oriI-dependent VPg uridylylation.

Pathak HB, Oh HS, Goodfellow IG, Arnold JJ, Cameron CE.

J Biol Chem. 2008 Nov 7;283(45):30677-88. doi: 10.1074/jbc.M806101200. Epub 2008 Sep 8.

16.
17.
18.

Picornavirus genome replication: assembly and organization of the VPg uridylylation ribonucleoprotein (initiation) complex.

Pathak HB, Arnold JJ, Wiegand PN, Hargittai MR, Cameron CE.

J Biol Chem. 2007 Jun 1;282(22):16202-13. Epub 2007 Mar 27.

19.

Crystal structure of poliovirus 3CD protein: virally encoded protease and precursor to the RNA-dependent RNA polymerase.

Marcotte LL, Wass AB, Gohara DW, Pathak HB, Arnold JJ, Filman DJ, Cameron CE, Hogle JM.

J Virol. 2007 Apr;81(7):3583-96. Epub 2007 Jan 24.

20.
21.

Stimulation of poliovirus synthesis in a HeLa cell-free in vitro translation-RNA replication system by viral protein 3CDpro.

Franco D, Pathak HB, Cameron CE, Rombaut B, Wimmer E, Paul AV.

J Virol. 2005 May;79(10):6358-67.

22.

Structure-function relationships of the RNA-dependent RNA polymerase from poliovirus (3Dpol). A surface of the primary oligomerization domain functions in capsid precursor processing and VPg uridylylation.

Pathak HB, Ghosh SK, Roberts AW, Sharma SD, Yoder JD, Arnold JJ, Gohara DW, Barton DJ, Paul AV, Cameron CE.

J Biol Chem. 2002 Aug 30;277(35):31551-62. Epub 2002 Jun 19.

23.

Proteinase-polymerase precursor as the active form of feline calicivirus RNA-dependent RNA polymerase.

Wei L, Huhn JS, Mory A, Pathak HB, Sosnovtsev SV, Green KY, Cameron CE.

J Virol. 2001 Feb;75(3):1211-9.

Supplemental Content

Loading ...
Support Center